A Phase 3 interventional study of Placebo 2 mL auto-injector and Placebo 1 mL prefilled syringe in Plaque Psoriasis, sponsored by Novartis Pharmaceuticals. Completed at 22 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-10-11.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 54 studies testing secukinumab in Psoriasis — 5 open to participants now, 5 under way, none of them phase 3. secukinumab · Psoriasis.
Among the 54 studies testing secukinumab in Psoriasis, this one is the 28th largest by enrollment, is one of 2 that started in 2018, is one of 24 in phase 3, and was the 41st registered.
2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.
Browse Psoriasis studies →5 of the 54 studies testing secukinumab in Psoriasis are open now, in 5 countries. Recruiting first, the newest first:
University Hospital, Ghent · Sites in Belgium
Ages 18+
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18–75 · Healthy volunteers
University of Athens · Sites in Greece
Ages 18–80 · Healthy volunteers
University of California, San Francisco · Sites in United States
Ages 18+
Singapore General Hospital · Sites in Singapore
Ages 22–90
By country, each count listing its studies:
secukinumab: first FDA approval 2015 (COSENTYX), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
54 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 8 · Phase 3 24 · Phase 4 17
First in 2007; this study’s year is marked. 2 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 122 is above the median of 75 across 1,567 interventional studies indexed under Psoriasis.
Median enrollment 124 across the 54 interventional studies. Of the 46 that completed or were terminated, 38 (83%) have results posted.
This tab as a report to print or save as PDF → With an account.
39 of 54 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
68 studies in Psoriasis by Novartis: 3 open now, 4 under way, none of them phase 3. Of 61 finished, 41 (67%) have results posted.
Among the 68 studies in Psoriasis by Novartis, this one is the 33rd largest by enrollment of the 53 interventional ones that give a count, is one of 3 that started in 2018, is one of 30 in phase 3, and was the 51st registered.
Novartis’s Psoriasis studies by the year they started, since 2004.
None of the studies under way reaches primary completion within a year.
Among the 54 studies testing secukinumab in Psoriasis, from their registry updates:
Among Novartis’s 68 in Psoriasis:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary purpose of this study is to assess efficacy, safety and tolerability of a 2 mL pre-filled auto-injector (AI) of 300 mg secukinumab in patients with moderate to severe plaque psoriasis
This is a 52-weeks multicenter, randomized, double-blind, placebo-controlled, parallel-group trial in approximately 120 subjects with moderate to severe plaque-type psoriasis
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subjects eligible for inclusion in this study must have fulfilled all of the following criteria:
Moderate to severe psoriasis as defined at Randomization by:
Candidate for systemic therapy. This is defined as a subject having moderate to severe chronic plaque-type psoriasis that is inadequately controlled by
Exclusion Criteria:
Ongoing use of prohibited treatments. detailed in the protocol had to be adhered to. Subjects not willing to limit UV light exposure (e.g., sunbathing and/or the use of tanning devices) during the course of the study were considered not eligible for this study since UV light exposure was prohibited.
Note: administration of 6 weeks prior to Randomization or during the study period was also prohibited.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Placebo to secukinumab s.c., provided in 2 mL auto-injector form
Drug: Placebo 2 mL auto-injector
Placebo to secukinumab s.c., provided in 2 \* 1 ml prefilled syringe form
Drug: Placebo 1 mL prefilled syringe
Secukinumab 300 mg provided in 2 mL auto-injector form
Drug: Secukinumab 2 mL auto-injector
Secukinumab 300 mg provided as 2x 1 mL prefilled syringe of 150 mg/mL
Drug: Secukinumab 1 mL prefilled syringe
All Placebo patients until week 8 (included): 2 mL auto-injector Placebo + 2x 1 mL prefilled syringe Placebo s.c. at randomization, weeks 1, 2, 3, 4 and 8. PASI 90 responders at week 12: 2 mL auto-injector placebo + 2x 1 mL prefilled syringe Placebo s.c. at weeks 12, 13, 14, 15, 16 and every 4 weeks thereafter until week 48. PASI 90 non-responders at week 12: 2 mL secukinumab 300 mg auto-injector + 2x 1 mL prefilled syringe Placebo s.c. at weeks 12, 13, 14, 15, 16 and 4-weekly thereafter until week 48
Also known as: Placebo
All Placebo patients until week 8 (included): 2 mL auto-injector Placebo + 2x 1 mL prefilled syringe Placebo s.c. at randomization, weeks 1, 2, 3, 4 and 8. PASI 90 responders at week 12: 2 mL auto-injector Placebo + 2x 1 mL prefilled syringe Placebo s.c. at weeks 12, 13, 14, 15, 16 and every 4 weeks thereafter until week 48. PASI 90 non-responders at week 12: 2x 1 mL secukinumab 150 mg prefilled syringe + 2 mL auto-injector Placebo s.c. at weeks 12, 13, 14, 15, 16 and 4-weekly thereafter until week 48
Also known as: Placebo
2 mL secukinumab 300 mg auto-injector + 2x 1 mL prefilled syringe Placebo s.c. at randomization, weeks 1, 2, 3, 4, 8, 12, 13, 14, 15 , 16 and 4-weekly thereafter until week 48
2 x 1 mL secukinumab 150 mg prefilled syringe + 2 mL auto-injector Placebo s.c. at randomization, weeks 1, 2, 3, 4, 8, 12, 13, 14, 15, 16 and 4-weekly thereafter until week 48
PASI 75 Response After 12 Weeks of Treatment
Percentage of participants who achieve ≥ 75% reduction in PASI compared to baseline. A PASI (Psoriasis Area and Severity Index) score is a tool used to measure the severity and extent of psoriasis. The score ranges from 0 (no signs of psoriasis) to a theoretic maximum of 72. The intensity of redness, thickness and scaling of the psoriasis is assessed as none (0), mild (1), moderate (2), severe (3) or very severe (4).
Time frame: 12 weeks
IGA Mod 2011 0 or 1 Response After 12 Weeks of Treatment
Percentage of participants who achieve IGA mod 2011 0 or 1, and improved by at least 2 points on the IGA scale compared to baseline. This scale ranges from 0 (clear, no signs of psoriasis) to 4 (severe).
Time frame: 12 weeks
PASI 90 Response
Percentage of participants who achieve ≥ 90% reduction in PASI compared to baseline
Time frame: 12 weeks
PASI 50, 75, 90 and 100 and IGA Mod 2011 0 or 1 Response
Percentage of participants who achieve ≥ 50%, 75%, 90% and 100% reduction in PASI and achieve IGA mod 2011 0 or 1, and improved by at least 2 points on the IGA scale compared to baseline at each visit up to 52 weeks
Time frame: 52 weeks
Successful Self-injection
Subject usability (ability to follow instructions for use and potential use-related hazards) and satisfaction with the new secukinumab 2 mL AI utilizing a self-administered Self-Injection Assessment Questionnaire (SIAQ) and investigator/site staff observation of secukinumab 300 mg 2 mL AI administration. The Satisfaction with Self-Injection (SA) domain score ranges from 0 (worst experience) to 10 (best experience).
Time frame: From randomization until Week 28
Dermatology Life Quality Index, (DLQI) 0 or 1 Score (Total Score)
DLQI is a simple, compact, and practical questionnaire for use in a dermatology clinical setting to assess limitations related to the impact of skin disease. The instrument contains ten items dealing with the participant's skin. With the exception of Item Number 7, the participant responds on a four-point scale, ranging from "Very Much" (score 3) to "Not at All" or "Not relevant" (score 0). Item Number 7 is a multi-part item, the first part of which ascertains whether the participant's skin prevented them from working or studying (Yes or No, scores 3 or 0 respectively), and if "No," then the participant is asked how much of a problem the skin has been at work or study over the past week, with response alternatives being "A lot," "A little," or "Not at all" (scores 2, 1, or 0 respectively). The DLQI total score is derived by summing all item scores, which has a possible range of 0 to 30, with 30 corresponding to the worst quality of life, and 0 corresponding to the best.
Time frame: Change from Baseline up to 52 weeks
A total of 144 subjects were screened at 22 study centers in 6 countries, and 122 subjects were randomized.
| Milestone | Secukinumab 300 mg (2 mL AI) | Secukinumab 300 mg (2x 1 mL PFS) | Placebo | Placebo-Secukinumab 300 mg (2 mL AI) | Placebo-Secukinumab 300 mg (2 x 1 mL PFS) |
|---|---|---|---|---|---|
| Started | 41 | 41 | 40 | 0 | 0 |
| Completed | 41 | 39 | 37 | 0 | 0 |
| Not completed | 0 | 2 | 3 | 0 | 0 |
| Withdrew: Adverse event | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 0 | 0 | 2 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 | 0 | 0 |
| Milestone | Secukinumab 300 mg (2 mL AI) | Secukinumab 300 mg (2x 1 mL PFS) | Placebo | Placebo-Secukinumab 300 mg (2 mL AI) | Placebo-Secukinumab 300 mg (2 x 1 mL PFS) |
|---|---|---|---|---|---|
| Started | 41 | 39 | 4 | 16 | 17 |
| Completed | 40 | 34 | 3 | 16 | 16 |
| Not completed | 1 | 5 | 1 | 0 | 1 |
| Withdrew: Adverse event | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Pregnancy | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 3 | 1 | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 1 | 0 | 0 | 0 |
Percentage of participants who achieve ≥ 75% reduction in PASI compared to baseline. A PASI (Psoriasis Area and Severity Index) score is a tool used to measure the severity and extent of psoriasis. The score ranges from 0 (no signs of psoriasis) to a theoretic maximum of 72. The intensity of redness, thickness and scaling of the psoriasis is assessed as none (0), mild (1), moderate (2), severe (3) or very severe (4).
| Participants | Secukinumab 2 mL Auto-injector | Secukinumab 1 mL Prefilled Syringe | Placebo |
|---|---|---|---|
| PASI 75 Response After 12 Weeks of Treatment | 39 | 34 | 4 |
Percentage of participants who achieve IGA mod 2011 0 or 1, and improved by at least 2 points on the IGA scale compared to baseline. This scale ranges from 0 (clear, no signs of psoriasis) to 4 (severe).
| Participants | Secukinumab 2 mL Auto-injector | Secukinumab 1 mL Prefilled Syringe | Placebo |
|---|---|---|---|
| IGA Mod 2011 0 or 1 Response After 12 Weeks of Treatment | 31 | 28 | 3 |
Percentage of participants who achieve ≥ 90% reduction in PASI compared to baseline
| Participants | Secukinumab 2 mL Auto-injector | Secukinumab 1 mL Prefilled Syringe | Placebo |
|---|---|---|---|
| PASI 90 Response | 31 | 26 | 2 |
Percentage of participants who achieve ≥ 50%, 75%, 90% and 100% reduction in PASI and achieve IGA mod 2011 0 or 1, and improved by at least 2 points on the IGA scale compared to baseline at each visit up to 52 weeks
| Participants | Secukinumab 2 mL Auto-injector | Secukinumab 1 mL Prefilled Syringe | Placebo | Placebo-Secukinumab 300 mg (2 mL Auto-injector) | Placebo-Secukinumab 300 mg (2x 1 mL Prefilled Syringe) |
|---|---|---|---|---|---|
| PASI 50 | 41 | 40 | 4 | 15 | 15 |
| PASI 75 | 38 | 37 | 1 | 13 | 14 |
| PASI 90 | 30 | 28 | 0 | 12 | 14 |
| PASI 100 | 23 | 18 | 0 | 11 | 11 |
| IGA 0/1 | 30 | 33 | 0 | 12 | 13 |
Subject usability (ability to follow instructions for use and potential use-related hazards) and satisfaction with the new secukinumab 2 mL AI utilizing a self-administered Self-Injection Assessment Questionnaire (SIAQ) and investigator/site staff observation of secukinumab 300 mg 2 mL AI administration. The Satisfaction with Self-Injection (SA) domain score ranges from 0 (worst experience) to 10 (best experience).
| Scores on a scale | PRE- Module by Visit | POST-module by Visit | Absolute Change POST Module -PRE Module |
|---|---|---|---|
| Baseline | 5.75 ± 2.442 | — | — |
| Baseline (1) =POST-module at baseline visit | 5.75 ± 2.452 | 7.52 ± 2.046 | 1.77 ± 2.789 |
| Week 1 | 5.72 ± 2.463 | 8.11 ± 1.759 | 2.39 ± 3.169 |
| Week 4 | 5.70 ± 2.495 | 8.27 ± 1.731 | 2.57 ± 3.080 |
| Week 8 | 5.68 ± 2.490 | 8.62 ± 1.545 | 2.94 ± 2.869 |
| Week 12 | 5.70 ± 2.523 | 8.56 ± 1.623 | 2.86 ± 2.985 |
| Week 28 | 5.62 ± 2.485 | 8.69 ± 1.681 | 3.07 ± 3.238 |
DLQI is a simple, compact, and practical questionnaire for use in a dermatology clinical setting to assess limitations related to the impact of skin disease. The instrument contains ten items dealing with the participant's skin. With the exception of Item Number 7, the participant responds on a four-point scale, ranging from "Very Much" (score 3) to "Not at All" or "Not relevant" (score 0). Item Number 7 is a multi-part item, the first part of which ascertains whether the participant's skin prevented them from working or studying (Yes or No, scores 3 or 0 respectively), and if "No," then the participant is asked how much of a problem the skin has been at work or study over the past week, with response alternatives being "A lot," "A little," or "Not at all" (scores 2, 1, or 0 respectively). The DLQI total score is derived by summing all item scores, which has a possible range of 0 to 30, with 30 corresponding to the worst quality of life, and 0 corresponding to the best.
| Scores on a Scale | Secukinumab 2 mL Auto-injector | Secukinumab 1 mL Prefilled Syringe | Placebo |
|---|---|---|---|
| Week 12 | -13.21 ± 7.701 | -11.95 ± 7.861 | -1.97 ± 6.966 |
| Week 28 | -13.59 ± 7.639 | -12.23 ± 8.438 | -13.00 ± 12.490 |
| Week 52 | -12.44 ± 8.219 | -12.23 ± 8.408 | -14.33 ± 11.240 |
Collected over Adverse events were collected from first dose of study treatment until end of study treatment (Week 48) plus 4 weeks post treatment.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Secukinumab 300 mg (2 mL Auto-Injector) | 0/41 (0%) | 1/41 (2.4%) | 19/41 (46.3%) |
| Secukinumab 300 mg (2 x 1 mL PFS) | 0/41 (0%) | 3/41 (7.3%) | 16/41 (39%) |
| Any Secukinumab 300 mg (2 mL AI) | 0/57 (0%) | 1/57 (1.8%) | 24/57 (42.1%) |
| Any Secukinumab 300 mg (2 x 1 mL PFS) | 0/58 (0%) | 4/58 (6.9%) | 21/58 (36.2%) |
| Placebo | 0/40 (0%) | 0/40 (0%) | 5/40 (12.5%) |
| Any Secukinumab 300 mg | 0/115 (0%) | 5/115 (4.3%) | 45/115 (39.1%) |
| Event | Secukinumab 300 mg (2 mL Auto-Injector) | Secukinumab 300 mg (2 x 1 mL PFS) | Any Secukinumab 300 mg (2 mL AI) | Any Secukinumab 300 mg (2 x 1 mL PFS) | Placebo | Any Secukinumab 300 mg |
|---|---|---|---|---|---|---|
| AppendicitisInfections and infestations | 0/41 | 1/41 | 0/57 | 1/58 | 0/40 | 1/115 |
| COVID-19Infections and infestations | 0/41 | 1/41 | 0/57 | 1/58 | 0/40 | 1/115 |
| Device related infectionInfections and infestations | 1/41 | 0/41 | 1/57 | 0/58 | 0/40 | 1/115 |
| ConcussionInjury, poisoning and procedural complications | 0/41 | 1/41 | 0/57 | 1/58 | 0/40 | 1/115 |
| Head injuryInjury, poisoning and procedural complications | 0/41 | 1/41 | 0/57 | 1/58 | 0/40 | 1/115 |
| Road traffic accidentInjury, poisoning and procedural complications | 0/41 | 1/41 | 0/57 | 1/58 | 0/40 | 1/115 |
| SyncopeNervous system disorders | 0/41 | 1/41 | 0/57 | 1/58 | 0/40 | 1/115 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 0/41 | 0/41 | 0/57 | 1/58 | 0/40 | 1/115 |
| Event | Secukinumab 300 mg (2 mL Auto-Injector) | Secukinumab 300 mg (2 x 1 mL PFS) | Any Secukinumab 300 mg (2 mL AI) | Any Secukinumab 300 mg (2 x 1 mL PFS) | Placebo | Any Secukinumab 300 mg |
|---|---|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 6/41 | 6/41 | 8/57 | 8/58 | 0/40 | 16/115 |
| Upper respiratory tract infectionInfections and infestations | 3/41 | 4/41 | 4/57 | 6/58 | 1/40 | 10/115 |
| HeadacheNervous system disorders | 2/41 | 4/41 | 3/57 | 4/58 | 1/40 | 7/115 |
| HypertensionVascular disorders | 4/41 | 2/41 | 5/57 | 2/58 | 0/40 | 7/115 |
| NauseaGastrointestinal disorders | 0/41 | 3/41 | 0/57 | 3/58 | 0/40 | 3/115 |
| Influenza like illnessGeneral disorders | 3/41 | 3/41 | 4/57 | 3/58 | 1/40 | 7/115 |
| PruritusSkin and subcutaneous tissue disorders | 3/41 | 2/41 | 3/57 | 3/58 | 2/40 | 6/115 |
Full Analysis set (FAS) consisted of 122 subjects and used for efficacy analyses.
| Age, Customized(Participants) | Secukinumab 2 mL Auto-injector | Secukinumab 1 mL Prefilled Syringe | Placebo | Total |
|---|---|---|---|---|
| < 65 | 39 | 37 | 36 | 112 |
| ≥ 65 | 2 | 4 | 4 | 10 |
| Sex: Female, Male(Participants) | Secukinumab 2 mL Auto-injector | Secukinumab 1 mL Prefilled Syringe | Placebo | Total |
|---|---|---|---|---|
| Female | 13 | 12 | 12 | 37 |
| Male | 28 | 29 | 28 | 85 |
| Race (NIH/OMB)(Participants) | Secukinumab 2 mL Auto-injector | Secukinumab 1 mL Prefilled Syringe | Placebo | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 0 | 1 |
| Asian | 1 | 1 | 3 | 5 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 0 | 0 | 1 |
| White | 39 | 39 | 37 | 115 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Ran from Dec 2018 to primary completion in Nov 2019, 11 months.
Results were first posted in Aug 2021, 1 year 9 months after primary completion. A results delay was requested in Feb 2020.
Of 217 industry-sponsored phase 3 interventional studies under Psoriasis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 11 months is below that.
Counting every sponsor, half of 227 studies reached it within 15 months; a quarter within 10 and three quarters within 26.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Secukinumab